JP2009509941A5 - - Google Patents

Download PDF

Info

Publication number
JP2009509941A5
JP2009509941A5 JP2008531412A JP2008531412A JP2009509941A5 JP 2009509941 A5 JP2009509941 A5 JP 2009509941A5 JP 2008531412 A JP2008531412 A JP 2008531412A JP 2008531412 A JP2008531412 A JP 2008531412A JP 2009509941 A5 JP2009509941 A5 JP 2009509941A5
Authority
JP
Japan
Prior art keywords
phe
aromatic
lys
arg
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008531412A
Other languages
English (en)
Japanese (ja)
Other versions
JP5416971B2 (ja
JP2009509941A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/036291 external-priority patent/WO2007035640A2/en
Publication of JP2009509941A publication Critical patent/JP2009509941A/ja
Publication of JP2009509941A5 publication Critical patent/JP2009509941A5/ja
Application granted granted Critical
Publication of JP5416971B2 publication Critical patent/JP5416971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008531412A 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法 Active JP5416971B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71817005P 2005-09-16 2005-09-16
US60/718,170 2005-09-16
PCT/US2006/036291 WO2007035640A2 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012181082A Division JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Division JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法

Publications (3)

Publication Number Publication Date
JP2009509941A JP2009509941A (ja) 2009-03-12
JP2009509941A5 true JP2009509941A5 (enExample) 2009-10-01
JP5416971B2 JP5416971B2 (ja) 2014-02-12

Family

ID=37889419

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2008531412A Active JP5416971B2 (ja) 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法

Country Status (10)

Country Link
US (10) US7541340B2 (enExample)
EP (5) EP3725324A1 (enExample)
JP (6) JP5416971B2 (enExample)
KR (9) KR20150013353A (enExample)
CN (6) CN103784937B (enExample)
AU (1) AU2006292352B2 (enExample)
CA (8) CA2947341C (enExample)
DK (1) DK1931369T3 (enExample)
HK (1) HK1206971A1 (enExample)
WO (1) WO2007035640A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3479838A1 (en) 2003-02-04 2019-05-08 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
EP1625149B1 (en) 2003-05-01 2016-02-17 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
CN103784937B (zh) 2005-09-16 2017-04-26 科内尔研究基金会 用于减少cd36表达的方法
JP5453320B2 (ja) 2008-02-07 2014-03-26 コーネル ユニヴァーシティー インスリン抵抗性を防止または処置するための方法
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
JP2012521355A (ja) * 2009-03-20 2012-09-13 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル 熱傷及び二次性合併症の予防及び治療方法
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
EP3292868A1 (en) 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CA2776581C (en) * 2009-10-05 2020-12-15 Cornell University Methods for the prevention or treatment of heart failure
EP2910250A1 (en) * 2009-12-31 2015-08-26 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
JP2013516426A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 冠状動脈バイパス移植術を行うための方法
CN103037901B (zh) * 2010-06-01 2018-04-27 康奈尔大学 抑制cd36以控制肥胖和胰岛素敏感性
CN106620645A (zh) * 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
EP3479839A1 (en) * 2012-02-22 2019-05-08 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
WO2013149172A1 (en) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
CA2880648A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
CN105051534B (zh) * 2012-12-18 2017-08-18 佰鸥科瑞公司 用于治疗和/或限制糖尿病发展的方法
JP2016522196A (ja) * 2013-05-14 2016-07-28 ステルス バイオセラピューティックス コープ 左室リモデリングの予防または治療のための方法
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
CN106163537A (zh) * 2013-09-30 2016-11-23 康奈尔大学 心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
EP3082838A4 (en) * 2013-12-16 2017-07-26 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US11392555B2 (en) 2019-05-15 2022-07-19 Pure Storage, Inc. Cloud-based file services
US20220288013A1 (en) * 2019-07-26 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University 1,8-cineol coated implants
EP4061402A4 (en) 2019-11-20 2023-12-06 The Board of Trustees of the Leland Stanford Junior University PROPHYLACTIC SKIN TREATMENT FOR RADIATION THERAPY
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
AU2024298726A1 (en) 2023-07-27 2026-02-19 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2085865T3 (es) 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2329709A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
ATE432993T1 (de) 1999-10-04 2009-06-15 Univ New Jersey Med Tar rna bindende peptide
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
DE10051983A1 (de) 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
AP2034A (en) * 2000-10-20 2009-08-28 Hamburger Stiftung Zur Forderung Wissenschaft Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
EP1383483A4 (en) 2001-04-05 2006-08-09 Collagenex Pharm Inc CONTROLLED RELEASE OF TETRACYCLIN COMPOUNDS AND TETRACYCLINE DERIVATIVES
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002360460A1 (en) * 2001-12-03 2003-06-17 Nuvelo, Inc. Methods and materials relating to novel polypeptides and polynucleotides
JP4346870B2 (ja) * 2002-07-05 2009-10-21 キッコーマン株式会社 血糖値上昇抑制用組成物
WO2004017986A1 (en) * 2002-08-23 2004-03-04 Valorisation-Recherche, Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
EP3479838A1 (en) * 2003-02-04 2019-05-08 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
EP1625149B1 (en) 2003-05-01 2016-02-17 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
US20050012597A1 (en) 2003-07-02 2005-01-20 Anderson Peter Traneus Wireless electromagnetic tracking system using a nonlinear passive transponder
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
CN1913774A (zh) 2003-12-12 2007-02-14 独立行政法人科学技术振兴机构 表达MEGSIN/RAGE/iNOS的疾病模型动物及借助于该动物评估化合物的方法
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US8157123B2 (en) * 2005-02-23 2012-04-17 The Glad Products Company Container
CN103784937B (zh) 2005-09-16 2017-04-26 科内尔研究基金会 用于减少cd36表达的方法
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
JP5453320B2 (ja) * 2008-02-07 2014-03-26 コーネル ユニヴァーシティー インスリン抵抗性を防止または処置するための方法
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
JP2012181082A (ja) * 2011-03-01 2012-09-20 Tokyo Electric Power Co Inc:The 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法
CN202756379U (zh) 2012-07-13 2013-02-27 滨中元川金属制品（昆山）有限公司 一种自攻牙螺丝

Similar Documents

Publication Publication Date Title
JP2009509941A5 (enExample)
JP2012525844A5 (enExample)
Fernandez‐Yague et al. A self‐powered piezo‐bioelectric device regulates tendon repair‐associated signaling pathways through modulation of mechanosensitive ion channels
JP2023058575A5 (enExample)
JP2022105138A5 (enExample)
JP2006524034A5 (enExample)
JP2009501732A5 (enExample)
JP2011515407A5 (enExample)
Shifman et al. Expression of the netrin receptor UNC-5 in lamprey brain: modulation by spinal cord transection
JP2009511579A5 (enExample)
JP2012507271A5 (enExample)
JP2013538560A5 (enExample)
CN1200127A (zh) 新的阿片样肽
JP2010533705A5 (enExample)
MX2015003841A (es) Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica.
JP2006502702A5 (enExample)
JP2010530238A5 (enExample)
JP2013510169A5 (enExample)
CN110381976A (zh) 包括肽wkdeagkplvk的组合物
TWI629279B (zh) 氧硼環戊烷酯類和彼等之用途
JP2004531242A5 (enExample)
JP2006506942A5 (enExample)
JP2013523718A5 (enExample)
JP2022531728A (ja) 胆汁酸塩ヒドロラーゼを使用して消化管を調節するための組成物及び方法
JP5749651B2 (ja) 多形核細胞の動員および／または遊走を減少させる化合物および方法